Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENGRUI PHARMA's SHR-4610 Injection Approved for Clinical Trials
Recommend 3 Positive 4 Negative 1 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd. (literal translation of "上海盛迪醫藥有限公司"), has received notification from the National Medical Products Administration (NMPA) that the clinical trial for SHR-4610 injection has been approved and will commence shortly. The SHR-4610 injection is intended for the treatment of advanced solid tumors. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
